Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Liabilities and Shareholders Equity (2017 - 2025)

Serina Therapeutics (SER) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 3.38% to $7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.0 million through Dec 2025, down 1.92% year-over-year, with the annual reading at $7.0 million for FY2025, 3.38% up from the prior year.
  • Liabilities and Shareholders Equity hit $7.0 million in Q4 2025 for Serina Therapeutics, down from $12.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $12.5 million in Q1 2023 to a low of $2.0 million in Q3 2022.
  • Historically, Liabilities and Shareholders Equity has averaged $6.9 million across 5 years, with a median of $6.8 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: tumbled 46.58% in 2021 and later skyrocketed 508.07% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $3.2 million in 2021, then increased by 2.76% to $3.2 million in 2022, then skyrocketed by 176.7% to $9.0 million in 2023, then fell by 25.02% to $6.7 million in 2024, then increased by 3.38% to $7.0 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for SER at $7.0 million in Q4 2025, $12.4 million in Q3 2025, and $8.9 million in Q2 2025.